ArticleAbdominal radiology (New York)2026
Development and validation of CT-based nomograms for predicting recurrence and prognosis in gastrointestinal stromal tumor.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of nomograms and predictive tools in gastrointestinal stromal tumor.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study analyzed preoperative CT features and postoperative pathological factors to predict recurrence after curative resection in primary gastrointestinal stromal tumor (GIST) and evaluate the prognostic validity of adjuvant therapy.
methodsWe retrospectively examined 718 patients with pathologically confirmed primary GISTs (mean age 57 ± 12.1 years; range, 14-86 years; 368 males, 350 females), who underwent R0 resection across two hospitals (internal set: n = 624; external set: n = 94). The internal set was randomly divided into training (n = 437) and validation cohorts (n = 187). Predictive efficacy of our nomogram was compared with the modified National Institutes of Health (MNIH) criterion using Kaplan-Meier analysis and multivariable Cox regression for recurrence-free survival (RFS).
resultsFor recurrence prediction, AUC values for the CT model, combined nomogram (integrating CT features and pathological features), and MNIH criterion were 0.867/0.786/0.917 (training/validation/external test) and 0.890/0.810/0.953 versus 0.791/0.739/0.894, respectively. The combined nomogram demonstrated superior efficacy to the MNIH criterion across most probability thresholds (P < 0.001). The prognostic nomogram stratified patients into 'high-recurrence' and 'low-recurrence' groups with significantly divergent RFS. In the training cohort, the 1-, 3-, 5-, and 7-year RFS rates of these two groups were 95.9%, 85%, 73.5%, and 62.2% versus 100%, 99%, 95.5%, and 95.5%, respectively (P < 0.001). In the validation and external test cohorts, the nomograms were still significantly efficient (P < 0.001).
conclusionsThe combined nomogram provides improved noninvasive prediction of GIST recurrence and prognosis compared to the MNIH criterion.
trial registrationApproved by the Institutional Review Board of West China Hospital, Sichuan University (No. 2020-249).
Indexed as
Identifiers
41186711What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.